Regulation in Hemostasis and Thrombosis: Part I—In Vitro Diagnostics

Emmanuel J. Favaloro; Mario Plebani; Giuseppe Lippi

doi:10.1055/s-0033-1336833

Seminars in Thrombosis and Hemostasis, Inhaltsverzeichnis

Semin Thromb Hemost 2013; 39(03): 235-249
DOI: 10.1055/s-0033-1336833

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Regulation in Hemostasis and Thrombosis: Part I—In Vitro Diagnostics

Emmanuel J. Favaloro

¹Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Pathology West, Westmead Hospital, Westmead, New South Wales, Australia

,

Mario Plebani

²Department of Laboratory Medicine, University-Hospital, Padova, Italy

,

Giuseppe Lippi

³Department of Pathology and Laboratory Medicine, Clinical Chemistry and Hematology Laboratory, Academic Hospital of Parma, Italy

› Institutsangaben

Abstract

The diagnostic or test-performance process, as associated to the evaluation or diagnosis of hemostasis and thrombosis and related disorders, is influenced or controlled by the activity of a large number of professional, expert, and government organizations. These may be involved in driving standardization or harmonization, providing professional or expert guidelines, or in regulation of therapeutic products and diagnostic products such as in vitro diagnostic devices or reagents (IVDs). Although all organizations involved in this activity would propose an intention to drive improvements in diagnostics and human health and although there are benefits to the overall process of standardization and regulation for tests of hemostasis and thrombosis, it should also be recognized there are several specific problems and limitations to this process. As highlighted in this report, which specifically relates to the regulation of IVDs, several case studies are used as examples to show that regulation, aimed to reduce risks associated with the implementation of diagnostic testing, may instead encourage the adverse outcome of locking out clinically useful, new, and improved technologies and locking in old and outdated technologies. This has a potential for significant adverse outcomes related to the clinical diagnosis and management of hemostasis and thrombosis-related disorders.

Keywords

standardization - regulation - harmonization - hemostasis testing - diagnostic practice - in vitro diagnostics - IVDs

Volltext

Referenzen

References
1 Lippi G, Favaloro EJ, Franchini M, Guidi GC. Milestones and perspectives in coagulation and hemostasis. Semin Thromb Hemost 2009; 35 (1) 9-22
2 Favaloro EJ, Lippi G. Coagulation update: what's new in hemostasis testing?. Thromb Res 2011; 127 (Suppl. 02) S13-S16
3 Lippi G, Favaloro EJ. Laboratory hemostasis: milestones in Clinical Chemistry and Laboratory Medicine. Clin Chem Lab Med 2013; 51 (1) 91-97
4 Lippi G, Mattiuzzi C. Testing volume is not synonymous of cost, value and efficacy in laboratory diagnostics. Clin Chem Lab Med 2013; 51 (2) 243-245
5 Lippi G, Simundic AM. Laboratory networking and sample quality: a still relevant issue for patient safety. Clin Chem Lab Med 2012; 50 (10) 1703-1705
6 Adams O, Cooper G, Fraser C , et al. Collective opinion paper on findings of the 2011 convocation of experts on laboratory quality. Clin Chem Lab Med 2012; 50 (9) 1547-1558
7 Sédille-Mostafaie M, Engler H, Lutz S, Korte W. Advancing haemostasis automation - successful implementation of robotic centrifugation and sample processing in a tertiary service hospital. Clin Chem Lab Med 2013;
8 Favaloro EJ, Mohammed S, Pati N, Ho MY, McDonald D. A clinical audit of congenital thrombophilia investigation in tertiary practice. Pathology 2011; 43 (3) 266-272
9 Favaloro EJ, Reben R, Mohammed S, Koutts J. Clinical audit of antiphospholipid antibody testing in tertiary practice: towards improved relevance in thrombophilia investigations. Intern Med J 2012; 42 (4) 427-434
10 Favaloro EJ, McDonald D. Futility of testing for factor V Leiden. Blood Transfus 2012; 10 (3) 260-263
11 Favaloro EJ, Lippi G. Laboratory testing and/or monitoring of the new oral anticoagulants/antithrombotics: for and against?. Clin Chem Lab Med 2011; 49 (5) 755-757
12 Favaloro EJ, Lippi G. The new oral anticoagulants and the future of haemostasis laboratory testing. Biochem Med (Zagreb) 2012; 22 (3) 329-341
13 Favaloro EJ, Lippi G, Koutts J. Laboratory testing of anticoagulants: the present and the future. Pathology 2011; 43 (7) 682-692
14 Samama MM, Guinet C. Laboratory assessment of new anticoagulants. Clin Chem Lab Med 2011; 49 (5) 761-772
15 Tripodi A, Di Iorio G, Lippi G, Testa S, Manotti C. Position paper on laboratory testing for patients taking new oral anticoagulants. Consensus document of FCSA, SIMeL, SIBioC and CISMEL. Clin Chem Lab Med 2012; 50 (12) 2137-2140
16 Harenberg J, Giese C, Marx S, Krämer R. Determination of dabigatran in human plasma samples. Semin Thromb Hemost 2012; 38 (1) 16-22
17 Harenberg J, Erdle S, Marx S, Krämer R. Determination of rivaroxaban in human plasma samples. Semin Thromb Hemost 2012; 38 (2) 178-184
18 Harenberg J, Du S, Krämer S , et al. Novel methods for assessing oral direct factor Xa and thrombin inhibitors: use of point of care testing and urine samples. Semin Thromb Hemost 2013; 39 (1) 66-71
19 Favaloro EJ, Plebani M, Lippi G. Quality in hemostasis and thrombosis—part I. Semin Thromb Hemost 2012; 38 (6) 549-552
20 Hughes S. Lab automation services. J Lab Autom 2012; 17 (6) 405-407
21 van Geffen M, van Heerde WL. Global haemostasis assays, from bench to bedside. Thromb Res 2012; 129 (6) 681-687
22 Lippi G, Plebani M. Continuous-flow automation and hemolysis index: a crucial combination. J Lab Autom 2012;
23 Barletta G, Zaninotto M, Faggian D, Plebani M. Shop for quality or quantity? Volumes and costs in clinical laboratories. Clin Chem Lab Med 2013; 51 (2) 295-301
24 Zaninotto M, Plebani M. The “hospital central laboratory”: automation, integration and clinical usefulness. Clin Chem Lab Med 2010; 48 (7) 911-917
25 Favaloro EJ. Standardization, regulation, quality assurance and emerging technologies in hemostasis: issues, controversies, benefits, and limitations. Semin Thromb Hemost 2007; 33 (3) 290-297
26 International organization for Standardization. ISO 17511: 2003. In vitro medical devices-measurement of quantities in biological samples-metrological traceability of values assigned to calibrators and controls. Geneva, Switzerland: 2003
27 Siekmann L. Metrological traceability - a concept for standardization in laboratory medicine. Clin Chem Lab Med 2013;
28 Olson JD, Preston FE, Nichols WL. External quality assurance in thrombosis and hemostasis: an international perspective. Semin Thromb Hemost 2007; 33 (3) 220-225
29 Favaloro EJ, Plebani M, Lippi G. Regulation of in vitro diagnostics (IVDs) for use in clinical diagnostic laboratories: towards the light or dark in clinical laboratory testing?. Clin Chem Lab Med 2011; 49 (12) 1965-1973
30 Favaloro EJ. Regulation of in vitro diagnostics (IVDs) for use in Australian pathology laboratories: a gloomy outlook for future pathology testing in this country?. Pathology 2011; 43 (4) 397-402
31 Favaloro EJ. Harmonising quality to the lowest clinical diagnostic standard? The case against regulation of in vitro diagnostics (IVDs) for use in clinical diagnostic laboratories. Australian Journal of Medical Science 2010; 31: 56-64
32 Sadler JE, Budde U, Eikenboom JCJ , et al; Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4 (10) 2103-2114
33 Nichols WL, Hultin MB, James AH , et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14 (2) 171-232
34 Favaloro EJ. Von Willebrand disease: local diagnosis and management of a globally distributed bleeding disorder. Semin Thromb Hemost 2011; 37 (5) 440-455
35 Favaloro EJ. New developments in the diagnosis and treatment of von Willebrand disease. Clin Investig 2012; 2 (8) 781-795
36 Favaloro EJ. Rethinking the diagnosis of von Willebrand disease. Thromb Res 2011; 127 (Suppl. 02) S17-S21
37 Favaloro EJ, Franchini M, Lippi G. Biological therapies for von Willebrand disease. Expert Opin Biol Ther 2012; 12 (5) 551-564
38 Favaloro EJ. An update on the von Willebrand factor collagen binding assay: 21 years of age and beyond adolescence but not yet a mature adult. Semin Thromb Hemost 2007; 33 (8) 727-744
39 Favaloro EJ. Toward a new paradigm for the identification and functional characterization of von Willebrand disease. Semin Thromb Hemost 2009; 35 (1) 60-75
40 Favaloro EJ. Diagnosis and classification of von Willebrand disease: a review of the differential utility of various functional von Willebrand factor assays. Blood Coagul Fibrinolysis 2011; 22 (7) 553-564
41 Favaloro EJ, Bonar R, Chapman K, Meiring M, Adcock DF. Differential sensitivity of von Willebrand factor ‘activity’ assays to large and small VWF molecular weight forms: a cross-laboratory study comparing ristocetin cofactor, collagen binding and monoclonal antibody based assays. J Thromb Haemost 2012; 10 (6) 1043-1054
42 Favaloro EJ, Bonar R, Kershaw G , et al. Reducing errors in identification of von Willebrand disease: the experience of the royal college of pathologists of australasia quality assurance program. Semin Thromb Hemost 2006; 32 (5) 505-513
43 Favaloro EJ, Bonar R, Kershaw G , et al; Royal College Of Pathologists Of Australasia Quality Assurance Program In Haematology. Laboratory diagnosis of von Willebrand disorder: use of multiple functional assays reduces diagnostic error rates. Lab Hematol 2005; 11 (2) 91-97
44 Hayes TE, Brandt JT, Chandler WL , et al. External peer review quality assurance testing in von Willebrand disease: the recent experience of the United States College of American Pathologists proficiency testing program. Semin Thromb Hemost 2006; 32 (5) 499-504
45 Meijer P, Haverkate F. An external quality assessment program for von Willebrand factor laboratory analysis: an overview from the European concerted action on thrombosis and disabilities foundation. Semin Thromb Hemost 2006; 32 (5) 485-491
46 Kitchen S, Jennings I, Woods TA, Kitchen DP, Walker ID, Preston FE. Laboratory tests for measurement of von Willebrand factor show poor agreement among different centers: results from the United Kingdom National External Quality Assessment Scheme for Blood Coagulation. Semin Thromb Hemost 2006; 32 (5) 492-498
47 Chandler WL, Peerschke EIB, Castellone DD, Meijer P. NASCOLA Proficiency Testing Committee. Von Willebrand factor assay proficiency testing. The North American Specialized Coagulation Laboratory Association experience. Am J Clin Pathol 2011; 135 (6) 862-869
48 Favaloro EJ, Bonar R, Marsden K. Lower limit of assay sensitivity: an under-recognised and significant problem in von Willebrand disease identification and classification. Clin Lab Sci 2008; 21 (3) 178-183
49 Flood VH, Friedman KD, Gill JC , et al. Limitations of the ristocetin cofactor assay in measurement of von Willebrand factor function. J Thromb Haemost 2009; 7 (11) 1832-1839
50 Flood VH, Gill JC, Morateck PA , et al. Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor. Blood 2010; 116 (2) 280-286
51 Miller CH, Haff E, Platt SJ , et al. Measurement of von Willebrand factor activity: relative effects of ABO blood type and race. J Thromb Haemost 2003; 1 (10) 2191-2197
52 Flood VH, Lederman CA, Wren JS , et al. Absent collagen binding in a VWF A3 domain mutant: utility of the VWF:CB in diagnosis of VWD. J Thromb Haemost 2010; 8 (6) 1431-1433
53 Hampshire DJ, Goodeve AC. The international society on thrombosis and haematosis von Willebrand disease database: an update. Semin Thromb Hemost 2011; 37 (5) 470-479
54 Adcock DM, Bethel M, Valcour A. Diagnosing von Willebrand disease: a large reference laboratory's perspective. Semin Thromb Hemost 2006; 32 (5) 472-479
55 Favaloro EJ, Thom J, Patterson D , et al. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?. Thromb Res 2009; 123 (6) 862-868
56 EUROPEAN COMMISSION. Proposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL on in vitro diagnostic medical devices. COM(2012) 541 final 2012/0267 (COD); available at: http://ec.europa.eu/health/medical-devices/documents/revision/index_en.htm ; accessed 21 ^st November 2012
57 Favaloro EJ. Evaluation of commercial von Willebrand factor collagen binding assays to assist the discrimination of types 1 and 2 von Willebrand disease. Thromb Haemost 2010; 104 (5) 1009-1021
58 Ni Y, Nesrallah J, Agnew M, Geske FJ, Favaloro EJ. Establishment and characterization of a new and stable collagen-binding assay for the assessment of von Willebrand factor activity. Int J Lab Hematol 2013; 35 (2) 170-176
59 Favaloro EJ, Adcock DM. Standardization of the INR: how good is your laboratory's INR and can it be improved?. Semin Thromb Hemost 2008; 34 (7) 593-603
60 Favaloro EJ, McVicker W, Hamdam S, Hocker N. Improving the harmonisation of the International Normalized Ratio (INR): time to think outside the box?. Clin Chem Lab Med 2010; 48 (8) 1079-1090
61 Clinical and Laboratory Standards Institute. Procedures for Validation of INR and Local Calibration of PT/INR Systems; Approved Guideline. CLSI document H54-A [ISBN 1-56238-580-1]. Wayne, PA: Clinical and Laboratory Standards Institute; 2005
62 van den Besselaar AMHP, Barrowcliffe TW, Houbouyan-Réveillard LL , et al; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the ISTH. Guidelines on preparation, certification, and use of certified plasmas for ISI calibration and INR determination. J Thromb Haemost 2004; 2 (11) 1946-1953
63 Poller L. Taberner, D A. Dosage and control of oral anticoagulants: an international collaborative survey. Br J Haematol 1982; 51 (3) 479-485
64 Olson JD, Brandt JT, Chandler WL , et al. Laboratory reporting of the international normalized ratio: progress and problems. Arch Pathol Lab Med 2007; 131 (11) 1641-1647
65 Favaloro EJ, Wong RC. Laboratory testing for the antiphospholipid syndrome: making sense of antiphospholipid antibody assays. Clin Chem Lab Med 2011; 49 (3) 447-461
66 Favaloro EJ, Wong RCW. The antiphospholipid syndrome: a large elephant with many parts or an elusive chameleon disguised by many colours?. Autoimmunity Highlights 2010; 1: 5-14
67 Miyakis S, Lockshin MD, Atsumi T , et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4 (2) 295-306
68 Kershaw G, Suresh S, Orellana D, Nguy YM. Laboratory identification of lupus anticoagulants. Semin Thromb Hemost 2012; 38 (4) 375-384
69 Adams M. Measurement of lupus anticoagulants: an update on quality in laboratory testing. Semin Thromb Hemost 2013; 39 (3) 267-271
70 Froom P, Barak M. Testing for lupus anticoagulants—fresh or frozen?. Clin Chem Lab Med 2012; 50 (9) 1607-1609
71 Harris EN, Gharavi AEM, Boey ML , et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; 2 (8361) 1211-1214
72 Favaloro EJ, Wheatland L, Jovanovich S, Roberts-Thomson P, Wong RCW. Internal quality control and external quality assurance in testing for antiphospholipid antibodies: Part I—Anticardiolipin and anti-β2-glycoprotein I antibodies. Semin Thromb Hemost 2012; 38 (4) 390-403
73 Favaloro EJ. Trials and tribulations in lupus anticoagulant testing. Clin Chem Lab Med 2013; 51 (2) 253-256
74 Favaloro EJ, Bonar R, Marsden K. Internal quality control and external quality assurance in testing for antiphospholipid antibodies: Part II—Lupus anticoagulant. Semin Thromb Hemost 2012; 38 (4) 404-411
75 Favaloro EJ, Silvestrini R, Mohammed A. Clinical utility of anticardiolipin antibody assays: high inter-laboratory variation and limited consensus by participants of external quality assurance programs signals a cautious approach. Pathology 1999; 31 (2) 142-147
76 Reber G, Arvieux J, Comby E , et al. Multicenter evaluation of nine commercial kits for the quantitation of anticardiolipin antibodies. The Working Group on Methodologies in Haemostasis from the GEHT (Groupe d'Etudes sur l'Hémostase et la Thrombose). Thromb Haemost 1995; 73 (3) 444-452
77 Favaloro EJ, Wong RC, Silvestrini R, McEvoy R, Jovanovich S, Roberts-Thomson P. A multilaboratory peer assessment quality assurance program-based evaluation of anticardiolipin antibody, and beta2-glycoprotein I antibody testing. Semin Thromb Hemost 2005; 31 (1) 73-84
78 Wong RC, Adelstein S, Gillis D, Favaloro EJ. Development of consensus guidelines for anticardiolipin and lupus anticoagulant testing. Semin Thromb Hemost 2005; 31 (1) 39-48
79 Reber G, Boehlen F, de Moerloose P. Technical aspects in laboratory testing for antiphospholipid antibodies: is standardization an impossible dream?. Semin Thromb Hemost 2008; 34 (4) 340-346
80 Pierangeli SS, Harris EN. A quarter of a century in anticardiolipin antibody testing and attempted standardization has led us to here, which is?. Semin Thromb Hemost 2008; 34 (4) 313-328
81 Lakos G, Favaloro EJ, Harris EN , et al. International consensus guidelines on anticardiolipin and anti-β2-glycoprotein I testing: report from the 13th International Congress on Antiphospholipid Antibodies. Arthritis Rheum 2012; 64 (1) 1-10
82 Pierangeli SS, Favaloro EJ, Lakos G , et al. Standards and reference materials for the anticardiolipin and anti-β2glycoprotein I assays: a report of recommendations from the APL Task Force at the 13th International Congress on Antiphospholipid Antibodies. Clin Chim Acta 2012; 413 (1–2) 358-360
83 Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101 (5) 1827-1832
84 Galli M, Luciani D, Bertolini G, Barbui T. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003; 102 (8) 2717-2723
85 Galli M, Reber G, de Moerloose P, de Groot PG. Invitation to a debate on the serological criteria that define the antiphospholipid syndrome. J Thromb Haemost 2008; 6 (2) 399-401
86 de Groot PG, Derksen RH, de Laat B. Twenty-two years of failure to set up undisputed assays to detect patients with the antiphospholipid syndrome. Semin Thromb Hemost 2008; 34 (4) 347-355
87 de Groot PG, Urbanus RT. The future of antiphospholipid antibody testing. Semin Thromb Hemost 2012; 38 (4) 412-420
88 Urbanus RT, de Groot PG. Antiphospholipid antibodies—we are not quite there yet. Blood Rev 2011; 25 (2) 97-106
89 Whicher JT, Ritchie RF, Johnson AM , et al. New international reference preparation for proteins in human serum (RPPHS). Clin Chem 1994; 40 (6) 934-938
90 Lippi G, Favaloro EJ, Plebani M. Direct-to-consumer testing: more risks than opportunities. Int J Clin Pract 2011; 65 (12) 1221-1229
91 Plebani M, Lippi G. Direct-to-consumer genomewide profiling. N Engl J Med 2011; 364 (21) 2074-2075 , author reply 2075
92 Plebani M. The CCLM contribution to improvements in quality and patient safety. Clin Chem Lab Med 2013; 51 (1) 39-46
93 Lippi G, Salvagno GL, Montagnana M, Lima-Oliveira G, Guidi GC, Favaloro EJ. Quality standards for sample collection in coagulation testing. Semin Thromb Hemost 2012; 38 (6) 565-575
94 Adcock Funk DM, Lippi G, Favaloro EJ. Quality standards for sample processing, transportation, and storage in hemostasis testing. Semin Thromb Hemost 2012; 38 (6) 576-585